Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial.

ABSTRACT:

Objective

To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing-targeted CMV testing (HT-cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT-cCMV testing programs.

Study design

Prospective survey of birth hospitals performing early CMV testing.

Setting

Multiple institutions.

Methods

Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT-cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT-cCMV screening and specific scre

SUBMITTER: Orb QT 

PROVIDER: S-EPMC11060929 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature